Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interleukin-2 SA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Interleukin-2 SA | DRUG | HAART and Bay 50-4798 |
| HAART | DRUG | HAART alone |
Inclusion Criteria: * Documented HIV infection (positive enzyme linked immuno assay (EIA) confirmed by Western Blot). * Age greater than or equal to 18 years. * Plasma HIV viral load less than 10,000 copies/ml (by bDNA assay or less than 14,000 copies/ml by RT-PCR) on at least 2 occasions within 8 ...
Top 20 of 28 competitors
Interleukin-2 SA is an investigational small molecule being developed for the treatment of HIV infections. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and its safety and efficacy are still being evaluated in clinical trials.
Interleukin-2 SA is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker symbol BAYRY. The drug is currently in Phase 1 clinical development for the treatment of HIV infections.
Interleukin-2 SA is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of HIV infections and has not yet received regulatory approval. One Phase 1 clinical trial has been completed for this drug.
Interleukin-2 SA has one completed Phase 1 clinical trial, identified as NCT00059462, titled "Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection." This randomized, double-blind, active-controlled trial enrolled 56 participants with HIV infections across the United States, France, and the United Kingdom.
Yes, Interleukin-2 SA is also known as BAY 50-4798. In clinical trial NCT00059462, the drug is referred to as BAY 50-4798, and it is being studied for the treatment of HIV infections.